Enhabit, Inc./$EHAB

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Enhabit, Inc.

Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.

Ticker

$EHAB
Sector

Primary listing

NYSE

Employees

10,700

Enhabit, Inc. Metrics

BasicAdvanced
$401M
-
-$0.23
1.32
-

What the Analysts think about Enhabit, Inc.

Majority rating from 8 analysts.
Hold

Bulls say / Bears say

In Q2 2025, Enhabit's hospice net service revenue rose 19.4% year over year to $60.2 million, average daily census increased 12.3%, and segment adjusted EBITDA surged 53.8%, underscoring robust demand in its hospice services (Nasdaq)
In Q3 2025, the hospice segment delivered net service revenue of $63.1 million (up 20.0% year over year) and saw adjusted EBITDA jump 72.0% while cost per patient day declined 3.1%, reflecting operational leverage in hospice care (SEC)
Enhabit strengthened its balance sheet in Q2 2025 by reducing bank debt by $10 million and prepaying a total of $45 million since Q1 2024, lowering interest expense by $3.2 million and enhancing liquidity (Business Wire)
Enhabit's home health net service revenue declined 2.0% year over year to $205.9 million in Q2 2025, and gross margin contracted to 47.9%, highlighting reimbursement pressures in its core home health business (Business Wire)
In Q3 2025, Enhabit's home health Medicare average daily census fell 1.4% year over year, with non-Medicare admissions growing just 4.5%, indicating ongoing challenges stabilizing key referral channels (Nasdaq)
Home health segment profitability in Q3 2025 weakened as segment adjusted EBITDA margin narrowed to 16.9% from 18.2% a year earlier, pointing to cost management and pricing headwinds (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 11 Nov 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EHAB

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs